Author: admin

Royalty Settlement in Patent Infringement Suit with New Strategic Partnership Formation for AI Marketing Tech Company: Alpha Modus, Corp. (Nasdaq: AMOD)

Royalty Settlement in Patent Infringement Suit with New Strategic Partnership Formation for AI Marketing Tech Company: Alpha Modus, Corp. (Nasdaq: AMOD)
$AMOD Reports Major Deployment of High Tech Financial Kiosks Targeting $75 Million Annual Revenue, Plus Ongoing Patent Infringement Actions vs. Walgreens and Other Top Retailers
  • Marketing Technology Company with a Core Focus on Artificial Intelligence (AI) in The Broad Retail Business Sector.
  • Strong Fundamentals, Ongoing Growth Strategy and Commitment to Delivering Value to AMOD shareholders
  • Large-Scale Deployment of AI Powered Financial Kiosks Across Vast Network of Supermarkets Targeting $75 Million in Annual Ad Revenue.
  • New Agreement with GlobeTopper to Boost Revenue Growth in Prepaid and Digital Transactions.
  • High Value Legal Settlement with Shelf Nine and Strategic Partnership Plans Including Perpetual License for AMOD Patented Innovations.
  • Ongoing Patent Infringement Actions vs. Walgreens and Other Top Retailers.
  • Retail Expansion Targeting $75 Million in Annual Ad Revenue.

Alpha Modus Corp. (Nasdaq: AMOD) is a technology company with a core focus on artificial intelligence (AI) in retail business. Alpha Moduscovers a variety of inventory management and advertising features, including the presentation and display of relevant and targeted advertising that is based on customer shopping habits, foot traffic, or other criteria. The Company engages in creating, developing and licensing data-driven technologies to enhance consumers’ in-store digital experience at the point of decision.

Landmark Settlement with Open Door for a Game-Changing Partnership

On March 17th AMOD announced a groundbreaking settlement in its patent infringement lawsuit against Wakefern and Shelf Nine. As part of this resolution, AMOD and Shelf Nine have reached a settlement agreement, while Shelf Nine’s parent company, VSBLTY Groupe Technologies Corp. will negotiate a strategic partnership for the deployment of AMOD cutting-edge technology which would include a perpetual license for AMOD patented innovations.

The lawsuit—one of several filed by AMOD against major retailers and digital signage networks, including Walgreens, Kroger, Wakefern, Shelf Nine, and Brookshire Grocery—centered on proprietary technology designed to enhance digital engagement and data-driven retail solutions. This agreement not only validates AMOD intellectual property rights but also establishes a long-term opportunity to integrate AMOD technology with VSBLTY’s proprietary and robust data analytics software once VSBLTY Groupe Technologies and AMOD finalize their strategic partnership agreement.

Through the proposed partnership agreement, Shelf Nine’s parent company VSBLTY Groupe Technologies will leverage AMOD proprietary solutions to enhance its retail media network, providing advertisers and retailers with state-of-the-art tools to optimize in-store customer engagement. This settlement and future strategic alliance reinforce both companies’ market position while opening new avenues for growth and technology deployment.

Furthermore, AMOD believes that numerous companies are currently infringing on its patent portfolio. This settlement strengthens the company’s ability to pursue further enforcement actions and ensures that its innovative technologies are recognized and respected throughout the industry. AMOD remains steadfast in protecting its intellectual property and will take decisive action, if necessary, to uphold its rights.

AMOD believes the investment community will closely monitor the implications of this agreement, as it not only fortifies the AMOD intellectual property portfolio but also demonstrates its ability to drive sustained value through both innovation and strategic partnerships—while underscoring its commitment to enforcing its IP rights when required.

AI-Powered Retail Expansion Targeting $75 Million in Annual Ad Revenue

On February 13th AMOD forecasted substantial growth as its partner, CashX, and began the large-scale deployment of its financial kiosks across a vast network of supermarkets beginning in California and Colorado. With a contracted deployment expected in approximately 10,000 locations, this initiative represents a transformational moment for AMOD and its investors.

“We see our AI technology revolutionizing the self-service financial kiosk industry, creating an entirely new revenue stream while providing critical services to millions of consumers,” said AMOD CEO William Alessi. “With projected advertising revenue alone reaching $75 million annually, we plan on delivering scalable, high-margin revenue growth for our investors during the deployment period. This deployment is intended to solidify our market leadership and position Alpha Modus as the backbone of AI-driven financial automation in retail.”

Each AMOD AI-powered CashX kiosk is expected to serve 1,250 unique visitors per month, reaching 150 million unique visits per year in the aggregate once all of the kiosks are fully deployed. This high engagement is projected to generate $75 million in annual ad revenue for Alpha Modus, significantly boosting Alpha Modus’s financial outlook.

Strategic Reseller Agreement with GlobeTopper (Symbol: ASII), Expanding Revenue Opportunities in Prepaid and Digital Transactions

On February 10th AMOD announced a strategic reseller agreement with GlobeTopper (OTC: ASII), a premier platform for prepaid products and digital transaction solutions. This partnership should strengthen both the AMOD and ASII market positions and create new revenue streams through an innovative revenue-sharing model. For more information on ASII GlobeTopper visit www.globetopper.com/. Under this agreement, AMOD gains the exclusive right to resell GlobeTopper’s suite of digital transaction solutions—including prepaid cards, event tickets, cryptocurrency services, and remittance products—to a targeted network of retailers where CashX AI-powered kiosks are deployed. The integration of ASII CashX AI into AMOD technology ecosystem enhances the accessibility and automation of digital financial transactions, further differentiating the Company in the evolving retail technology landscape.

Alpha Modus CEO Addresses Market Volatility and Recent SPAC Merger

On January 30th Alpha Modus CEO William Alessi, issued a statement regarding company’s strong fundamentals, ongoing growth strategy and commitment to delivering value to AMOD shareholders amidst what he described as “uninformed speculation” by certain market participants.

“The recent sell side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the ‘de-SPAC norm,’” said Alessi. “This trend is emblematic of broader market dynamics in the SPAC environment, where some investors prioritize short-term speculation over informed, long-term investment. In recent years, it’s been the norm to compete for the exit door as so many of these SPAC transactions had finance structures surrounding the de-SPAC that encouraged selling. Unlike most SPAC transactions in recent years, we worked diligently to secure prudent closing terms in our merger. We did not allow the issuance of commitment shares or warrants at a zero-cost basis that would otherwise incentivize selling. We did just the opposite. We painfully renegotiated existing sponsor side fees and reduced share issuances to the extent we could.”

AMOD successfully transitioned from its SPAC merger to a publicly traded entity, a process that has unlocked new opportunities for growth and innovation. Despite these achievements, the CEO pointed out that management believes certain market players have underestimated the company’s robust operational model, IP catalogue and significant pipeline of strategic initiatives.

For more information on $AMOD visit: alphamodus.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Alpha Modus Corp.
Contact Person: Investor Relations
Email: Send Email
Phone: (704) 252-5050
Address:20311 Chartwell Center Dr Suite 1469
City: Cornelius
State: North Carolina
Country: United States
Website: https://alphamodus.com/

Vybrational Kreators: The Evolution of Streetwear into Luxury Fashion

In the realm of high-end fashion, a new force is emerging that is challenging the traditional norms of luxury fashion. That force is Vybrational Kreators, a luxury streetwear brand that is transforming how we view street culture and high fashion. Unlike any other brand on the market, Vybrational Kreators blends the rugged, authentic vibe of streetwear with the prestige and elegance of luxury fashion, creating a new era of style for the modern trendsetter.

With a focus on exclusive designs, superior craftsmanship, and an innovative approach to fashion, Vybrational Kreators has become the go-to choice for those who desire to express their individuality while embracing luxury. The brand is more than just clothing—it’s a statement of who you are, what you stand for, and how you choose to present yourself to the world.

The Vision Behind Vybrational Kreators

Vybrational Kreators isn’t just about producing stylish pieces—it’s about offering a lifestyle. The brand is rooted in the idea that fashion should reflect personal vibrations and individuality. The name “Vybrational” itself alludes to the energy each piece carries, making every garment a unique representation of the wearer’s essence.

At the core of Vybrational Kreators is a commitment to merging the boldness of streetwear with the sophistication of luxury. Whether it’s a premium hoodie, sleek joggers, or a designer duffel bag, each item is crafted with the intention of standing out while offering a premium, comfortable fit.

A Modern Twist on Streetwear

Vybrational Kreators redefines streetwear by making it luxurious without losing its raw, urban edge. The brand’s collections include high-quality hoodies, graphic t-shirts, stylish joggers, premium bags, beanies, and hats—each piece designed to push boundaries while maintaining an approachable, versatile aesthetic.

What sets Vybrational Kreators apart from other streetwear brands is the attention to detail. The garments and accessories aren’t just designed for everyday wear—they’re crafted to create an experience. Each hoodie, jacket, or pair of joggers is carefully made with premium materials that ensure comfort, durability, and luxury all at once. It’s streetwear that doesn’t compromise on style or quality.

Premium Quality Meets Streetwise Cool

One of the key elements that defines Vybrational Kreators is its commitment to superior craftsmanship. Each piece in the collection is designed and produced with an uncompromising focus on quality. Whether it’s the soft cotton in their t-shirts or the durable canvas used for their bags, the brand uses only the finest materials to ensure each item feels as good as it looks.

Vybrational Kreators doesn’t just create fashion; they create pieces that last. Every hoodie, pair of joggers, and bag is made to stand the test of time, keeping you stylish for years to come. With their modern, minimalistic designs and luxurious construction, Vybrational Kreators’ clothing becomes more than just an item in your wardrobe—it’s an investment in long-lasting fashion and quality.

Accessories That Complete the Look

In addition to the high-end streetwear pieces, Vybrational Kreators also offers a range of luxury accessories that elevate any outfit. From designer hats and premium beanies to exclusive duffel bags and luxury sneakers, each accessory is a work of art designed to add that final touch of sophistication to your streetwear look.

The duffel bags, for example, are made from high-quality leather and durable fabrics, perfect for carrying your essentials in style. The brand’s hats and beanies are not just about keeping warm—they’re a fashion statement in their own right, offering a refined yet urban touch to any outfit.

Vybrational Kreators: More Than Just a Brand

Vybrational Kreators is not just about luxury fashion; it’s about belonging to a community of individuals who understand the intersection of style and substance. The brand caters to those who value authenticity, who see fashion as a reflection of their unique personality. Wearing Vybrational Kreators means aligning yourself with a movement—one that celebrates individual expression, quality craftsmanship, and luxury streetwear.

For those who are not content with simply following trends, Vybrational Kreators offers the opportunity to set your own. It’s a brand that stands at the crossroads of high fashion and street culture, bringing a refreshing perspective to a fashion world often dominated by fast trends and fleeting styles.

The Future of Vybrational Kreators

As Vybrational Kreators continues to grow, the brand is poised to expand its influence in both the streetwear and luxury fashion spaces. With its commitment to innovation, quality, and unique design, the future is bright for Vybrational Kreators.

For those who are ready to experience the next wave of luxury fashion, Vybrational Kreators offers a chance to be part of a cutting-edge movement. It’s not just about what you wear—it’s about how you wear it and the energy you bring to the world. Vybrational Kreators invites you to join this evolution of style and embrace the future of luxury streetwear.

Media Contact
Company Name: McNear Agency Services
Contact Person: McNear Agency Marketing Services
Email: Send Email
Country: United States
Website: https://www.mcnearagencyservices.com/marketing

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vybrational Kreators: The Evolution of Streetwear into Luxury Fashion

Fina Health Addresses End of Tirzepatide and Semaglutide Shortages Amid Continued High Costs

Miami, FL – March 17, 2025 – The recent conclusion of the nationwide shortage of popular weight-loss medications Tirzepatide and Semaglutide has done little to ease patient struggles, as high prescription costs persist, creating significant barriers to treatment. In response, Fina Health, a leader in comprehensive telehealth weight-loss solutions, has amplified its commitment to empowering patients through conservative, sustainable health measures.

While the medication shortage was challenging, its resolution has not translated into affordability for many patients, with pricing remaining prohibitively high. Recognizing this ongoing issue, Fina Health emphasizes evidence-based, conservative treatments including dietary guidance, personalized exercise regimens, and professional nutritional counseling to ensure sustainable weight loss results.

“Our mission at Fina Health has always been to deliver holistic care that promotes lasting wellness,” said Dr. Sam Searcy, founder of Fina Health. “While we recognize the value of medications like Tirzepatide and Semaglutide, we firmly believe in optimizing conservative measures first, empowering patients with practical tools and lifestyle adjustments that lead to sustainable, long-term success.”

Fina Health’s integrative approach combines telehealth convenience with personalized lifestyle management, ensuring patients receive comprehensive care that addresses both short-term needs and long-term health goals.

For more information about Fina Health’s holistic weight-loss solutions, please visit finamd.com

About Fina Health:

Fina Health is a telehealth platform based in Florida, dedicated to providing accessible, comprehensive weight-loss solutions. Emphasizing conservative approaches such as dietary education, exercise planning, and nutritional counseling, Fina Health empowers patients to achieve lasting wellness through sustainable health strategies.

Media Contact
Company Name: Fina Health
Contact Person: Sam Searcy
Email: Send Email
Phone: 1-645-223-7888
City: Miami
State: FL 33137
Country: United States
Website: finamd.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fina Health Addresses End of Tirzepatide and Semaglutide Shortages Amid Continued High Costs

Ankylosing spondylitis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharma

The Key Ankylosing spondylitis Companies in the market include – Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others.

 

The Ankylosing spondylitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ankylosing spondylitis pipeline products will significantly revolutionize the Ankylosing spondylitis market dynamics.

 

DelveInsight’s “Ankylosing spondylitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ankylosing spondylitis, historical and forecasted epidemiology as well as the Ankylosing spondylitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Ankylosing spondylitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Ankylosing spondylitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ankylosing spondylitis Market Forecast

 

Some of the key facts of the Ankylosing spondylitis Market Report:

  • The Ankylosing spondylitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In February 2025, UCB Canada Inc. has successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for BIMZELX® (bimekizumab), following positive reimbursement recommendations from both Canada’s Drug Agency (CDA) and Quebec’s Institut National d’Excellence en Santé et en Services Sociaux (INESSS). These endorsements pertain to the treatment of adults with active psoriatic arthritis (PsA) and ankylosing spondylitis (AS). BIMZELX® is the first and only biologic approved in Canada that inhibits both IL-17A and IL-17F. Health Canada authorized its use for active PsA on February 23, 2024, and for axial spondyloarthritis, including AS, on March 11, 2024. The recent successful negotiations with pCPA are anticipated to facilitate public reimbursement, enhancing patient access to this innovative therapy.

  • In January 2025, Screening is currently underway for adults with active axial spondyloarthritis (axSpA), including ankylosing spondylitis, for a Phase 2 clinical trial in Germany testing sonelokimab. This nanobody, developed by Moonlake Immunotherapeutics, is being evaluated for its potential in treating inflammatory diseases of the skin and joints. The open-label study, named S-OLARIS (EudraCT 2024-513498-36), aims to assess the efficacy of sonelokimab in reducing inflammation in the spine and sacroiliac joints, which connect the spine to the pelvis. The trial plans to enroll approximately 25 patients, all of whom will receive a 60 mg dose of sonelokimab via subcutaneous injection.

  • In December 2024, Neuron23® Inc., a clinical-stage biotechnology company dedicated to precision medicines for genetically defined neurological and immunological diseases, announced the commencement of dosing in a Phase 1 clinical trial of NEU-111 in healthy volunteers. NEU-111 is a highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the JAK protein family involved in pathological immune signaling. With best-in-class potential, NEU-111 reduces signaling through multiple cytokine receptors, including those for interleukin (IL)-12, IL-23, and interferon (IFN). TYK2 is associated with various immune-mediated inflammatory diseases, including ankylosing spondylitis.

  • In 2023, the total prevalent population of ankylosing spondylitis in the 7MM region was approximately 2,300,000, with the highest number of cases observed in the United States.

  • In the 7MM, approximately 1,130,000 cases of diagnosed ankylosing spondylitis were reported in 2023. According to the analysis, these cases are projected to increase by 2034 with a moderate compound annual growth rate (CAGR).

  • In 2023, the United States reported the highest number of age-specific prevalent cases, with approximately 270,000 cases among individuals aged 40-59 years, followed by those under 40 years of age.

  • In 2023, Italy had the highest number of diagnosed prevalent cases of ankylosing spondylitis in the EU4 region, totaling approximately 192,000 cases.

  • Key Ankylosing spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others

  • Key Ankylosing spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others

  • The Ankylosing spondylitis epidemiology based on gender analyzed that Ankylosing spondylitis is more common in males than females

 

Ankylosing spondylitis Overview

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, leading to pain and stiffness. Over time, AS can cause the vertebrae in the spine to fuse, resulting in a loss of flexibility and a hunched-forward posture. In severe cases, it can lead to the spine becoming inflexible and rigid.

 

Get a Free sample for the Ankylosing spondylitis Market Report –

https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market

 

Ankylosing spondylitis Market

The dynamics of the Ankylosing spondylitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

 

Ankylosing spondylitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ankylosing spondylitis Epidemiology Segmentation:

The Ankylosing spondylitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalent cases of Ankylosing Spondylitis in the 7MM

  • Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM

  • Age-specific Diagnosed Prevalent Cases of Ankylosing Spondylitis in 7MM

  • Treated cases of Ankylosing Spondylitis in the 7MM

  • Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM

  • Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis in the 7MM

 

Download the report to understand which factors are driving Ankylosing spondylitis epidemiology trends @ Ankylosing spondylitis Epidemiological Insights

 

Ankylosing spondylitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ankylosing spondylitis market or expected to get launched during the study period. The analysis covers Ankylosing spondylitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ankylosing spondylitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Ankylosing spondylitis treatment, visit @ Ankylosing spondylitis Medications

 

Ankylosing spondylitis Therapies and Key Companies

  • KIN-1901: Kinevant Sciences

  • Sonelokimab: MoonLake Immunotherapeutics

  • QX 002N: Qyuns Therapeutics

  • SHR-1314: Suzhou Zelgen Biopharmaceuticals

  • SHR0302: Jiangsu HengRui MedicIne

  • Jaktinib: Suzhou Zelgen Biopharmaceuticals

  • Apremilast: Amgen

 

Ankylosing spondylitis Market Strengths

  • Certain initiatives have been taken by private and government organizations to raise awareness about the disease. The Spondylitis Association of America (SAA) began officially celebrating SpA Awareness Month in May.

  • There has been an increase in pharmaceutical companies’ investment in the research and development of drugs.

 

Ankylosing spondylitis Market Opportunities

  • Several pharmaceutical key players have taken the initiative to meet the unmet needs of the Ankylosing Spondylitis market’s present situation.

  • The prevalence of Ankylosing Spondylitis diagnosis codes more than doubled between 2006 and 2016; increase in prevalence creates a lucrative opportunity for the Ankylosing Spondylitis market.

 

Scope of the Ankylosing spondylitis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Ankylosing spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others

  • Key Ankylosing spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others

  • Ankylosing spondylitis Therapeutic Assessment: Ankylosing spondylitis current marketed and Ankylosing spondylitis emerging therapies

  • Ankylosing spondylitis Market Dynamics: Ankylosing spondylitis market drivers and Ankylosing spondylitis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Ankylosing spondylitis Unmet Needs, KOL’s views, Analyst’s views, Ankylosing spondylitis Market Access and Reimbursement

 

Discover more about therapies set to grab major Ankylosing spondylitis market share @ Ankylosing spondylitis Treatment Landscape

 

Table of Contents

1. Ankylosing spondylitis Market Report Introduction

2. Executive Summary for Ankylosing spondylitis

3. SWOT analysis of Ankylosing spondylitis

4. Ankylosing spondylitis Patient Share (%) Overview at a Glance

5. Ankylosing spondylitis Market Overview at a Glance

6. Ankylosing spondylitis Disease Background and Overview

7. Ankylosing spondylitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Ankylosing spondylitis

9. Ankylosing spondylitis Current Treatment and Medical Practices

10. Ankylosing spondylitis Unmet Needs

11. Ankylosing spondylitis Emerging Therapies

12. Ankylosing spondylitis Market Outlook

13. Country-Wise Ankylosing spondylitis Market Analysis (2020–2034)

14. Ankylosing spondylitis Market Access and Reimbursement of Therapies

15. Ankylosing spondylitis Market Drivers

16. Ankylosing spondylitis Market Barriers

17. Ankylosing spondylitis Appendix

18. Ankylosing spondylitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ankylosing spondylitis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharma

AlignD Redefines Self-Help for Fantasy Lovers, Revealing the Magic Hidden in Reality

For those who have ever longed for the magic of their favorite fantasy worlds to be real, Alignd.Fun offers an invitation to step into a life where wonder, synchronicity, and limitless potential are not only possible but natural.

Founded by a curious explorer who has studied energy medicine, hypnosis, and ancient wisdom across the globe, AlignD is a digital portal designed to help modern escapists rediscover their personal power and inner universe. Through immersive visualizations, guided perspective shifts, and storytelling, Alignd transforms everyday reality into a playground of magic and possibility.

At the heart of AlignD is a free weekly newsletter, a beacon for those seeking inspiration, empowerment, and gentle reminders that their words, thoughts, and energy shape the world around them. Subscribers receive exclusive guidance on shifting their mindset, tuning into their energy, and experiencing synchronicities that feel like stepping into a storybook where they are the protagonist.

Beyond the newsletter, Alignd offers curated courses, transformative visualizations, and energetic tools that teach people how to create their lives with intention and playfulness. Its latest creation, Your Word is Your Wand, is a deep dive into the power of language, showing how words act as spells that shape reality.

“In a world where so many people seek escape, AlignD is about returning—to yourself, your body, and your point of power,” says the founder. “It’s about realizing that the same wonder we chase in books and films is already present, waiting to be seen.”

AlignD’s work resonates with fantasy lovers, spiritual seekers, and anyone who senses there must be more to life than what meets the eye. By blending energetic principles, mindfulness, and a touch of enchantment, it offers a space where reality and imagination merge.

To step into the AlignD experience and begin exploring your inner universe, visit Alignd.Fun and sign up for the free newsletter.

Media Contact
Company Name: AlignD
Contact Person: Leora Calmus
Email: Send Email
Country: United States
Website: www.AlignD.fun

Power Anywhere, Anytime: How UDPOWER Redefines Portable Energy Solutions

With spring’s arrival comes renewed adventures and unpredictable weather, increasing the demand for reliable portable power. UDPOWER, as a deep-rooted player in the field of portable power, is fulfilling the needs of all scenarios in the home, emergency and outdoors with unrivaled safety, efficiency and environmental friendliness. Whether you’re camping, fishing, preparing for emergencies, or powering up at home, UDPOWER can ensure that you have power anytime, anywhere.

https://www.youtube.com/watch?v=Fe5_9xDyrCQ

UDPOWER, was founded in the U.S.A. and is a core member of a listed company. With 30 years of expertise, UDPOWER has redefined portable energy solutions—backed by a world-class team of 600+ engineers and a portfolio of industry-leading patents in battery management, inverter design, and structural engineering. As a core member of a listed company, UDPOWER combines innovation with proven safety and has provided trusted power solutions to 1.5 million users worldwide.

At the heart of UDPOWER’s success is its proprietary technology, developed entirely in-house, and an R&D team with over 30 years of expertise.Each UDPOWER product undergoes a rigorous 18-step testing process to ensure that it meets the highest standards before reaching the consumer. This dedication to quality has made UDPOWER a trusted name in the portable energy storage industry.

UDPOWER’s products are designed with a keen focus on user experience and safety. Its BMS 3.0 system leverages AI to monitor battery health in real time using 10 temperature sensors and 64 algorithms. It detects hazards like overcharging, over-discharging,short circuits, and thermal runaway at 50x/sec, achieving a 90% lower failure rate than the industry avg. The third-generation inverter is designed with a highly integrated MCU and optimized with AI algorithms to achieve stability and range and improve system performance through reactive power compensation.

UDPOWER’s products feature high performance, lightweight, environmentally friendly, and ultra-quiet operations to meet the needs of all users. Stay powered anywhere, anytime. Whether at home, on the road, or off the grid, UDPOWER offers versatile charging solutions—from fast AC charging to eco-friendly solar power and convenient car charging. Wherever you go, your power goes with you.

UDPOWER’s commitment to user-centered design goes beyond functional attributes. The sleek, ergonomic design ensures UDPOWER products are both powerful and aesthetically pleasing. Intuitive control panels and LED displays make it easy for users to view real-time information such as battery status, power output, and more. Their enclosures are made of reinforced PC+ABS with a 94V-0 fire rating, and rugged construction designed to withstand extreme conditions, even vehicle impact.

UDPOWER remains steadfast in its pursuit of excellence, continuously striving to innovate and contribute to sustainable development efforts. By pushing the boundaries of technology, UDPOWER aims to enhance product safety and performance while driving a greener, more sustainable future. Join the trusted choice of millions – UDPOWER, fueling your every adventure with a continuous supply of power.

Media Contact
Company Name: UDPOWER Inc.
Contact Person: Jacob Douglas
Email: Send Email
Country: United States
Website: https://udpwr.com/

Ceramic Edge Launches Exclusive Offer to Help Car Detailers 10x Their Business with Minimal Investment

The leading growth partner for car detailing businesses is thrilled to announce an exclusive offer for eight more detailers to join their proven program. This limited-time opportunity allows mobile and in-shop detailers to scale their businesses like never before, with a smaller investment and lower risk than traditional methods.

Car detailing professionals across North America are already experiencing unprecedented growth with Ceramic Edge’s innovative strategies. From increasing job volume to securing higher-paying customers and retaining clients longer, Ceramic Edge has helped detailers transform their businesses. In just the first month, many clients have gone from completing 2-4 ceramic coatings to over 10, with some achieving $8,000+ in revenue.

Ceramic Edge’s clients are seeing remarkable results:

– EC Car Detailing: Esteban generated $8,000 in ceramic coating revenue within his first 30 days.

– Diamond Detailing HS, TX: Completed eight ceramic coatings worth $5,700 just one month after joining.

– F1 Mobile Detailing: Earned $2,800 in ceramics within the first 20 days of partnering with Ceramic Edge.

These success stories highlight the program’s ability to deliver a strong return on investment (ROI) while minimizing risk.

In a 1-on-1 call, Ceramic Edge will reveal:

– How to consistently close 15-30 ceramic coating jobs per month using battle-tested digital marketing strategies.

– The secrets to dominating Facebook and Instagram to stand out in the competitive car detailing space.

– How to attract the most qualified, exclusive leads and close more revenue than ever before.

– Time-saving techniques to focus on what matters most—growing business and enjoying life.

This exclusive offer is available to only eight more detailers ready to take their businesses to the next level. Ceramic Edge’s transparent, results-driven approach ensures every detailer receives personalized support to achieve their goals.

About Ceramic Edge:

Ceramic Edge is a trusted growth partner for car detailers across North America. It specializes in helping businesses scale through innovative marketing, sales strategies, and client retention techniques. With a proven track record of success, Ceramic Edge is committed to helping detailers achieve their full potential.

Media Contact
Company Name: Ceramic Edge
Contact Person: Panos Katsis
Email: Send Email
Phone: +15855600456
Country: United States
Website: https://ceramic-edge.com

The Boulder Group Arranges Sale of Net Leased Pinnacle Bank in Nashville MSA

The Boulder Group, a net leased investment brokerage firm, completed the sale of a single tenant net leased Pinnacle Bank property located at 1717 Mallory Lane in Brentwood, TN for $6,500,000.

Pinnacle Bank operating under a 15-year NNN lease with over 12 years remaining. The lease features annual rent increases. Pinnacle Bank has strong annual deposits exceeding $323,000,000 at the subject location.

The property is strategically positioned along Mallory Lane (19,460 VPD) and is less than ½ mile west of Interstate 65 (150,085 VPD). The property benefits from its location 15 miles from downtown Nashville, the 35th most populous MSA in the United States.

Pinnacle Bank is situated in an outparcel of Costco in a very dense retail corridor. Prominent retailers nearby include Target, Home Depot, Best Buy, Floor & Décor, Academy Sports & Outdoors, Publix, The Cheesecake Factory, Olive Garden, Outback, Chick-fil-A, McDonald’s, Taco Bell, Cracker Barrel, Red Lobster, Chili’s, and Raising Cane’s.

The surrounding area is well populated and highly affluent, with a population of 102,374 within a 5-mile radius and an average household income of $184,699 within 5 miles.

Pinnacle Bank is an American bank that was founded in 2000 and is headquartered in Nashville, TN. As of 2025, Pinnacle Bank operates over 160 locations throughout the southeastern United States. The company is publicly traded (Nasdaq: PNFP) and is a component of the S&P 400. Pinnacle Bank is an investment-grade company (Moody’s: Baa2).

“Bank assets with lengthy lease terms in income tax-free states continue to garner significant investor interest”, said Randy Blankstein, President of The Boulder Group. Jimmy Goodman, Partner of The Boulder Group, added, “This property benefits from robust demographics and its location 15 miles from downtown Nashville.”

About The Boulder Group The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high net worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $9 billion of single tenant net lease real estate transactions. From 2014-2024, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both Real Capital Analytics and CoStar. The Boulder Group is headquartered in suburban Chicago.

www.bouldergroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Randy Blankstein
Email: Send Email
Phone: 8478816388
Address:3520 Lake Avenue Suite 203
City: Wilmette
State: Illinois
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Net Leased Pinnacle Bank in Nashville MSA

Chronic Spontaneous Urticaria Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

“Chronic Spontaneous Urticaria Treatment Market”
Chronic Spontaneous Urticaria Companies such as Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.

(Albany, USA) DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology and Market Forecast 2034” report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chronic Spontaneous Urticaria market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chronic Spontaneous Urticaria market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Chronic Spontaneous Urticaria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chronic Spontaneous Urticaria market.

 

Discover Key Insights into the Chronic Spontaneous Urticaria Market with DelveInsight’s In-Depth Report @ Chronic Spontaneous Urticaria Market Size

 

Key Takeaways from the Chronic Spontaneous Urticaria Market

  • According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of chronic spontaneous urticaria were approximately 2.8 million among the 7MM in 2023 which is expected to change during the forecast period (2024-2034).
  • In the US, there were approximately 521 thousand diagnosed prevalent cases of chronic spontaneous urticaria in 2023 which was nearly 19% of the total 7MM.
  • Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of chronic spontaneous urticarial in 2023 with approximately 327 thousand cases followed by France with nearly 255 thousand cases. On the other hand, Spain accounted for the least with approximately 163 thousand cases.
  • In 2023, Japan accounted for the highest diagnosed prevalent cases of chronic spontaneous urticaria with approximately 1 million cases.
  • Among the age-specific diagnosed prevalent cases of chronic spontaneous urticaria in the US, there were approximately 47 thousand, 80 thousand, 72 thousand, 81 thousand, 86 thousand, and 156 thousand cases in the age groups <18, 18−29, 30−39, 40−49, 50−59, and ≥60, respectively, in 2023.
  • There were approximately 391 thousand male and 839 thousand female cases of chronic spontaneous urticarial among EU4 and the UK in 2023.
  • In Japan, there were approximately 46 thousand mild cases, 690 thousand moderate cases, and 326 thousand severe cases of chronic spontaneous urticaria in 2023.
  • The leading Chronic Spontaneous Urticaria Companies such as Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
  • Promising Chronic Spontaneous Urticaria Therapies such as barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
  • In March 2025, Evommune, Inc announced results of a Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria
  • In March 2025, Jiangsu Hansoh Pharmaceutical Co., Ltd. announced results of a Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
  • In February 2025, Celldex Therapeutics announced results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)
  • In October 2024, Jasper Therapeutics announced the launch of an open-label extension study for CSU, enrolling patients from the BEACON and SPOTLIGHT trials after their initial follow-up. The company also received regulatory approval in the US and EU to add a 360mg single-dose cohort (n=4) to the BEACON study in CSU. Initial data from doses up to 240mg will be reported in January 2025, with 360mg cohort data expected in the first half of 2025.

 

Stay ahead in the Chronic Spontaneous Urticaria Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Spontaneous Urticaria Market Outlook

 

Chronic Spontaneous Urticaria Epidemiology Segmentation in the 7MM

  • Total Chronic Spontaneous Urticaria Diagnosed Prevalent Cases
  • Chronic Spontaneous Urticaria Type-specific Cases
  • Chronic Spontaneous Urticaria Gender-specific Cases
  • Chronic Spontaneous Urticaria Age-specific Cases
  • Chronic Spontaneous Urticaria Severity-specific Cases

 

Download the report to understand which factors are driving Chronic Spontaneous Urticaria epidemiology trends @ Chronic Spontaneous Urticaria Prevalence

 

Chronic Spontaneous Urticaria Treatment Market

The treatment of CSU is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a step-wise approach, starting with first-line treatments and progressing to more advanced options if necessary. Treatment is generally initiated with nonsedating antihistamines in the daytime and sedating antihistamines at night. H2-antihistamines are often combined with H1 to achieve better symptom control in CSU and are added if individuals complain of indigestion or acidity. The most commonly used H2 antihistamine for CSU is ranitidine. However, it is important to note that ranitidine has been withdrawn from many markets due to safety concerns. Many patients, however, do not achieve symptom control, with only less than half of patients responding to H1-antihistamines at standard doses. Adverse effects such as somnolence can occur in susceptible individuals, increasing the treatment burden, despite increasing the dose.

 

Chronic Spontaneous Urticaria Marketed Drugs

  • XOLAIR (omalizumab): Roche/Novartis
  • DUPIXENT (dupilumab): Sanofi/Regeneron

 

Chronic Spontaneous Urticaria Emerging Drugs Profile

  • Remibrutinib (LOU064): Novartis Pharmaceuticals
  • TEZSPIRE (tezepelumab): AstraZeneca/Amgen
  • Rilzabrutinib (SAR444671): Sanofi

 

Get In-Depth Knowledge on Chronic Spontaneous Urticaria Market Trends and Forecasts with DelveInsight @ Chronic Spontaneous Urticaria Treatment Market

 

Chronic Spontaneous Urticaria Therapeutics Market Landscape

Chronic spontaneous urticaria is a chronic condition characterized by the recurrent appearance of hives or wheals on the skin. It is a disturbing allergic condition of the skin, where symptoms persist for more than 6 weeks. The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.

 

Chronic Spontaneous Urticaria Market Outlook

Chronic spontaneous urticaria is a disturbing allergic condition of the skin where symptoms persist for more than 6 weeks. A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema. It often causes huge socio-economic distress for the patients, significantly impacting their quality of life. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.

The Chronic Spontaneous Urticaria (CSU) market is driven by several key factors, including the rising prevalence of the condition, increasing awareness among patients and healthcare professionals, and advancements in biologic therapies. The growing demand for targeted treatment options, particularly monoclonal antibodies like omalizumab, has significantly improved disease management, driving market growth. Additionally, ongoing research and development (R&D) efforts, along with a strong pipeline of novel therapeutics, are expected to further expand treatment options. However, the market faces several barriers, such as high treatment costs, limited access to advanced biologics in certain regions, and potential side effects associated with long-term use of biologic therapies. Additionally, misdiagnosis and underreporting of cases, particularly in developing countries, pose challenges to market expansion. Despite these obstacles, continued advancements in precision medicine, the emergence of next-generation biologics, and increased regulatory approvals are expected to create new opportunities for growth in the CSU market.

 

Chronic Spontaneous Urticaria Companies

Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.

 

Download DelveInsight’s Chronic Spontaneous Urticaria Market report today and stay ahead in this rapidly evolving field. @ Chronic Spontaneous Urticaria Clinical Trials

 

Scope of the Chronic Spontaneous Urticaria Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Chronic Spontaneous Urticaria Companies- Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
  • Chronic Spontaneous Urticaria Therapies- Barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
  • Chronic Spontaneous Urticaria Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Chronic Spontaneous Urticaria Unmet Needs, KOL’s views, Analyst’s views, Chronic Spontaneous Urticaria Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

4. Methodology of Chronic Spontaneous Urticaria Epidemiology and Market

5. Executive Summary of Chronic Spontaneous Urticaria

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Chronic Spontaneous Urticaria: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT

15. Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Spontaneous Urticaria Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

The Madina Bakers Opens First Storefront in Doha, Expanding Qatar’s Cookie Market

The bakery, founded by Ibrahim Majanini, brings a dedicated space for handcrafted cookies to Doha, offering a selection of flavors made with high-quality ingredients.

The Madina Bakers, a Qatar-based bakery that makes handcrafted cookies, has opened its first storefront in Doha. Founded by Ibrahim Majanini, the shop brings a dedicated platform for customers to experience a range of cookies made with high-quality ingredients.

The launch marks a milestone for Majanini, who started The Madina Bakers as a home-based project. With growing demand, the bakery has transitioned from a personal passion into a full-scale business offering customers a selection of freshly baked cookies.

“The Madina Bakers started from a simple idea: sharing cookies with friends and family,” Majanini said. “Opening this store allows us to bring that experience to more people in a warm and welcoming setting.”

The bakery’s menu features a variety of cookies, from rich chocolate-based options to citrus-infused flavors. Each batch is made using premium ingredients, including organic cane sugar, farm-fresh eggs, and high-quality butter.

The storefront is designed to create an inviting space where customers can enjoy freshly baked treats. The shop also offers gift packaging for those looking to share its signature cookies with others.

“The goal is to offer more than just cookies—we want to create a place where people can gather, enjoy a familiar taste, and make new memories,” Majanini said.

Located in Doha, The Madina Bakers is now open to customers. The bakery plans to expand its offerings while maintaining the quality and approach that have defined its success.

About The Madina Bakers

The Madina Bakers is an artisanal cookie shop based in Doha, Qatar. Founded by Ibrahim Majanini, the bakery specializes in handcrafted cookies made with high-quality ingredients. With a focus on traditional baking techniques and carefully selected flavors, The Madina Bakers offers a selection of cookies that blend nostalgia with modern tastes. 

For more information about how to join the Crumb Club, visit themadinabakers.com.

Media Contact
Company Name: The Madina Bakers
Contact Person: Ibrahim Majanini
Email: Send Email
Country: Qatar
Website: https://themadinabakers.com/